News BioCryst Pharmaceuticals, Inc.

Equities

BCRX

US09058V1035

Real-time Estimate Cboe BZX Other stock markets 01:00:39 2024-04-23 pm EDT			5-day change	1st Jan Change
4.515 ^USD	+2.38%		-1.74%	-24.38%

Apr. 17	BioCryst Pharmaceuticals Secures Approval for Orladeyo in Brazil	MT
Apr. 17	BioCryst Pharmaceuticals, Inc. Announces Approval of ORLADEYO (berotralstat) by the Brazilian Health Regulatory Agency	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioCryst to Report First Quarter 2024 Financial Results on May 6	Apr. 22	AQ
BioCryst Pharmaceuticals Secures Approval for Orladeyo in Brazil	Apr. 17	MT
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency	Apr. 17	AQ
BioCryst Pharmaceuticals, Inc. Announces Approval of ORLADEYO (berotralstat) by the Brazilian Health Regulatory Agency	Apr. 17	CI
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Apr. 03	AQ
BioCryst to Present at Upcoming Investor Conferences	Mar. 25	AQ
Transcript : BioCryst Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 07:30 AM	Mar. 12
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Mar. 05	AQ
Transcript : BioCryst Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 26, 2024	Feb. 26
BioCryst Pharmaceuticals Q4 Adjusted Loss Narrows as Revenue Increases	Feb. 26	MT
BioCryst: Q4 Earnings Snapshot	Feb. 26	AQ
BioCryst Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 26	CI
Earnings Flash (BCRX) BIOCRYST PHARMACEUTICALS Posts Q4 Revenue $93.4M, vs. Street Est of $90M	Feb. 26	MT
BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones	Feb. 26	AQ
Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2024	Feb. 26	CI
BioCryst Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 26	CI
North American Morning Briefing : Traders Await Inflation Data This Week	Feb. 26	DJ
BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO® (berotralstat) Treatment	Feb. 23	AQ
BioCryst to Present at Upcoming Investor Conferences	Feb. 21	AQ
BioCryst Launches Hereditary Angioedema Drug in Italy	Feb. 20	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News BioCryst Pharmaceuticals, Inc.

Equities

BCRX

US09058V1035

Summary

Filters